Combination therapy a promising option for advanced kidney cancer patients already treated with immunotherapy

Immunotherapies, such as anti-PD-1 and anti-PD-L1, have become standard first line therapies for patients with advanced renal cell carcinoma (kidney cancer). Most patients, however, eventually experience disease progression, with no consensus on what therapy to use next.

Leave A Comment

Your email address will not be published. Required fields are marked *